COMP <GO>
ROP vs TMO // FORWARD P/E MULTIPLE
Roper Technologies Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ROP 10
— TMO 5
▲ FORWARD P/E MULTIPLE LEADER: ROP
LAST: $466.60 (+3.77%) • MKT CAP: $44.47B
forward-pe
24.4x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROP VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROP | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.20% | 41.00% | +28.20 | ROP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.30% | 9.30% | -3.00 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.8x | 30.4x | -9.60 | ROP | /valuation <GO> |
| Free Cash Flow Yield | 4.91% | 2.40% | +2.51 | ROP | /fcf-yield <GO> |
| Operating Margin | 28.30% | 17.40% | +10.90 | ROP | /operating-margins <GO> |
| Net Profit Margin | 19.40% | 15.10% | +4.30 | ROP | /net-margins <GO> |
| Revenue Growth (YoY) | 12.30% | 3.90% | +8.40 | ROP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.80% | 0.24% | +0.56 | ROP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.89 | 4.50 | -1.61 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.70% | +0.40 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 82.2 | 59.1 | +23.05 | ROP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.94 | +0.11 | ROP | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 24.4x | 36.3x | -11.90 | ROP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $44.47B | $262.22B | -$217.75B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROP REV | TMO REV | ROP GROSS % | TMO GROSS % | ROP FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.90B | $44.56B | 69.2% | 44.0% | $2.18B | $6.29B |
| FY 2024 | $7.04B | $42.88B | 69.3% | 44.0% | $2.08B | $7.27B |
| FY 2023 | $6.18B | $42.86B | 44.0% | 44.0% | $1.76B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROP // BETA 1.05
TMO // BETA 0.94